-
IC Packianathan, NJ Fuller, DB Peterson, A Wright, WA Coward, N Finer. Use of a reference four-component model to evaluate the ability of alternative methods and prediction techniques to estimate body composition in Type 2 diabetes and its changes following insulin treatment. Int J Body Comp Research 2005;2 (4): 141-148.
-
Tuthill A, Slawik H, O’Rahilly, S, Finer N. Psychiatric co-morbidities in patients attending specialist obesity services in the UK. Quarterly Journal of Medicine 2006: 99:317-325
-
Lean MEJ & Finer N. ABC of obesity. Management: Part II—Drugs. BMJ 2006;333:794-797
-
Torp-Pedersen C, Caterson I, Coutinho W, Finer N, et al.. Cardiovascular Responses to Weight Management and Sibutramine in High-Risk Subjects – An Analysis from the SCOUT Trial. European Heart Journal 2007;28:2915-23
-
Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on body weight and type 2 diabetes: a review of the literature. Obesity Surgery 2007,17:1248-56.
-
Wolf AM, Finer N et al. PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: Baseline Health and Health Care. Utilization of the US Sample. Diabetes, Obesity Metabolism. 2008
-
Napolitano A, Miller SR, Murgatroyd PR, Coward WA, Wright A, Finer N, et al. Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity 2008;16:191-8
-
Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Practice, 2008.
-
James WPT, Caterson I, Coutinho W, Finer N et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese. New Engl J Med. 2010 363: 1905-17
-
Falaschetti E, Aroon D. Hingorani AD, Jones A, Charakida M, Finer N, Whincup P, Lawlor DA, Smith GD, Sattar N, Deanfield JE. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children European Heart Journal 2010 (epub 23.10.2010)
-
Aronne LJ, Finer N et al. Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance. Obesity (Silver Spring). 2011 Jul;19(7):1404-14.
-
Louise A. Savory, Catherine J., Kerr, Paul, Whiting, Nicholas, Finer, Jane, McEneny, Ashton T. Selenium Supplementation & Exercise: Effect on Oxidant Stress in Overweight Adults. Obesity in press March 2011
-
Astrup A, Al Hakim M, Carraro R, Finer N et al. Sustained Weight Loss with Diet and Liraglutide for Obesity: A 52-week Dose-ranging Randomized. Int J Obesity 2011 epub.
-
Counterweight Project Team. The implementation of the Counterweight Programme in Scotland, UK, Family Practice 2011. Epub 2011.
-
Tsigos C, Hainer V, Basdevant A, Finer N et al. Criteria for EASO-Collaborating Centres for Obesity Management. Obes Facts 2011;4:329–333.